In the BioHarmony Drug Report Database

"Preview" Icon

Galcanezumab

Emgality (galcanezumab) is an antibody pharmaceutical. Galcanezumab was first approved as Emgality on 2018-09-27. It is used to treat cluster headache in the USA. It has been approved in Europe to treat migraine disorders. The pharmaceutical is active against calcitonin; calcitonin gene-related peptide 1.

 

Trade Name

 

Emgality
 

Common Name

 

galcanezumab
 

ChEMBL ID

 

CHEMBL3707328
 

Indication

 

cluster headache, migraine disorders
 

Drug Class

 

Monoclonal antibodies: humanized, neural indications

Image (chem structure or protein)

Galcanezumab structure rendering